BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT^®

References

• Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization; 2003.
   Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69–77. doi:10.1111/j.1468-1331.2010.03110.x
   PubMed Web of Science ®Google Scholar
• Hansen K, Schüssel K, Kieble M, et al. Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort study. PLoS One. 2015;10(7):e0133279. doi:10.1371/journal.pone.0133279
   PubMed Web of Science ®Google Scholar
• Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89–100. doi:10.2165/11533330-000000000-00000
   PubMed Web of Science ®Google Scholar
• Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf. 2008;17(6):565–576. doi:10.1002/pds.1593
   PubMed Web of Science ®Google Scholar
• Rio J, Porcel J, Téllez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11(3):306–309. doi:10.1191/1352458505ms1173oa
   PubMed Web of Science ®Google Scholar
• Al-Sabbagh A, Bennett D, Kozma C, Dickson M, Meletiche D. Medication gaps in disease-modifying drug therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. J Neurol. 2008;255(suppl 2):S79.
   Google Scholar
• Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15(3):601–609. doi:10.3111/13696998.2012.667027
   PubMedGoogle Scholar
• Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon Outcomes Res. 2017;9:251–260. doi:10.2147/CEOR.S130334
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. doi:10.1056/NEJMra050100
   PubMed Web of Science ®Google Scholar
• Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, Phase IV study. BMC Neurol. 2012;12(1):7. doi:10.1186/1471-2377-12-7
   PubMed Web of Science ®Google Scholar
• Meyniel C, Spelman T, Jokubaitis VG, et al. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. PLoS One. 2012;7(6):e38661. doi:10.1371/journal.pone.0038661
   Web of Science ®Google Scholar
• Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256(4):568–576. doi:10.1007/s00415-009-0096-y
   PubMed Web of Science ®Google Scholar
• Lugaresi A, Rottoli MR, Patti F. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother. 2014;14(9):1029–1042. doi:10.1586/14737175.2014.945523
   PubMed Web of Science ®Google Scholar
• Morillo Verdugo R, Ramírez Herráiz E, Fernández-Del Olmo R, Roig Bonet M, Valdivia García M. Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain. Patient Prefer Adherence. 2019;13:261–272. doi:10.2147/PPA.S187983
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Schweikert B, Ecari U, Oentrich W, Bugge JP. Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study. J Neurol. 2012;259(11):2319–2328. doi:10.1007/s00415-012-6492-8
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Sylvester L, Rametta M, Ross AP. Patient satisfaction with the new interferon beta-1b autoinjector BETACONNECTTM. Neurol Ther. 2015;4(2):125–136. doi:10.1007/s40120-015-0036-y
   PubMedGoogle Scholar
• Barone DA, Singer BA, Merkov L, Rametta M, Suarez G. Survey of US patients with multiple sclerosis: comparison of the new electronic interferon beta-1b autoinjector (BETACONNECTTM) with mechanical autoinjectors. Neurol Ther. 2016;5(2):155–167. doi:10.1007/s40120-016-0047-3
   PubMed Web of Science ®Google Scholar
• Weller I, Saake A, Schreiner T, Vogelreuter J, Petroff N. Patient satisfaction with the BETACONNECTTM autoinjector for interferon beta-1b. Patient Prefer Adherence. 2015;9:951–959. doi:10.2147/PPA.S85917
   PubMed Web of Science ®Google Scholar
• Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047. doi:10.1155/2015/217047
   PubMed Web of Science ®Google Scholar
• Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19(1 Suppl A):S24–40. doi:10.18553/jmcp.2013.19.s1.S24
   PubMed Web of Science ®Google Scholar
• Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2006;38(3):167–171. doi:10.1097/01376517-200606000-00005
   Google Scholar
• Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008;255(suppl 6):87–92. doi:10.1007/s00415-008-6016-8
   PubMed Web of Science ®Google Scholar
• Arroyo E, González M, Grau C, et al. Proposals to improve adherence to immunomodulatory therapies in patients with multiple sclerosis. Neurología. 2010;25(9):544–551. doi:10.1016/j.nrl.2010.07.004
   Web of Science ®Google Scholar
• de Seze J, Borgel F, Brudon F. Patient perceptions of multiple sclerosis and its treatment. Patient Prefer Adherence. 2012;6:263–273. doi:10.2147/PPA.S27038
   PubMed Web of Science ®Google Scholar
• Conway D, Cecilia Vieira M, Thompson NR, Parker KN, Meng X, Fox R. Patient-reported disease-modifying therapy adherence in the clinic: a reliable metric? Mult Scler J Exp Transl Clin. 2018;4(2):2055217318777894.
   Google Scholar
• Limmroth V, Reischl J, Mann B, et al. Autoinjector preference among patients with multiple sclerosis: results from a national survey. Patient Prefer Adherence. 2017;11:1325–1334. doi:10.2147/PPA.S137741
   PubMed Web of Science ®Google Scholar
• Kleiter I, Lang M, Jeske J, Norenberg C, Stollfuss B, Schürks M. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study. BMC Neurol. 2017;17(1):174. doi:10.1186/s12883-017-0953-8
   Web of Science ®Google Scholar
• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120. doi:10.1177/1352458517751049
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European public assessment reports: background and context. Available from: https://www.ema.europa.eu/. Accessed December 13, 2019.
   Google Scholar
• COPAXONE® is approved for treatment of patients with a first clinical event suggestive of multiple sclerosis [ press release]. Jerusalem, Israel: BusinessWire; 2009. Available from: https://www.businesswire.com/news/home/20090204005697/en/COPAXONE%C2%AE-Approved-Treatment-Patients-Clinical-Event-Suggestive. Accessed December 13, 2019.
   Google Scholar
• Mylan, in partnership with Synthon, receives marketing authorization approval in Europe for first generic for Copaxone® 40 mg/mL [press release]. Hertfordshire, England: Mylan N.V. PRNewswire; 2017. Available from: http://newsroom.mylan.com/2017-10-05-Mylan-in-Partnership-with-Synthon-Receives-Marketing-Authorization-Approval-in-Europe-for-First-Generic-for-Copaxone-R-40-mg-mL. Accessed December 13, 2019.
   Google Scholar
• Ribes García S, Gómez-Pajares F, Albelda Puig C, García Herrera JL, Casanova Estruch B. Description of the characteristics of multiple sclerosis patients in the region of Valencia (Spain) who requested treatment with disease-modifying drugs during the 2005–2014 Decade. Eur Neurol. 2016;75(5–6):274–281. doi:10.1159/000446580
   Web of Science ®Google Scholar